Endo Pharmaceuticals Holdings
The 10-second takeaway
For the quarter ended March 31 (Q1), Endo Pharmaceuticals Holdings missed slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share dropped to a loss.
Margins contracted across the board.
Endo Pharmaceuticals Holdings recorded revenue of $690.6 million. The 20 analysts polled by S&P Capital IQ expected to see revenue of $701.3 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $560.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.87. The 23 earnings estimates compiled by S&P Capital IQ averaged $0.87 per share. GAAP EPS were -$0.75 for Q1 compared to $0.46 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.2%, 1,150 basis points worse than the prior-year quarter. Operating margin was -2.6%, 2,530 basis points worse than the prior-year quarter. Net margin was -12.6%, 2,260 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $789.8 million. On the bottom line, the average EPS estimate is $1.25.
Next year's average estimate for revenue is $3.22 billion. The average EPS estimate is $5.11.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 421 members out of 441 rating the stock outperform, and 20 members rating it underperform. Among 136 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 133 give Endo Pharmaceuticals Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Pharmaceuticals Holdings is outperform, with an average price target of $44.70.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Endo Pharmaceuticals Holdings the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Endo Pharmaceuticals Holdings to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.